2015 American Transplant Congress
First Clinical Data With an Improved C1q-Luminex® Assay
1Nephrology, Charite Hospital, Berlin, Germany; 2HLA Laboratory, Charite Hospital, Berlin, Germany.
Background: Chronic allograft dysfunction remains the main obstacle for long-term success of kidney transplantation. Immunological factors, in particular HLA-antibodies, contribute to long-term allograft loss. Identification…2015 American Transplant Congress
Accurate Prediction of High-Resolution HLA-A, -B, -C, -DRB1 and -DQB1 Typing and Low-Resolution HLA-DQA1 Typing by Haplotype Analysis
Aim: Allele-specific HLA antibodies are commonly detected by Luminex single antigen bead assays in solid organ transplant recipients. However, high-resolution HLA typing for deceased donors…2015 American Transplant Congress
Donor-Specific Alloantibody After Positive Crossmatch Kidney Transplantation With Eculizumab (EC): Correlation With Transplant Glomerulopathy and Graft Failure
1Mayo Clinic, Rochester, MN; 2Paul Terasaki Foundation, Los Angeles, CA.
Introduction. EC (C5 blockade) reduces the incidence of early clinical acute antibody mediated rejection (AMR) after +XMKTx, but does not prevent chronic AMR. We examined…2015 American Transplant Congress
Improved Long-Term Graft Survival in Renal Transplant Recipients With Donor Specific Antibodies (DSA) After Mycophenolic Acid Escalation
Background: DSA formation in post-renal transplant patients is associated with chronic rejection and graft failure. Previous studies in our population indicate DSA formation is a…2015 American Transplant Congress
Cyclophosphamide as a Salvage Therapy for Combined Intravenous Immunoglobulins and Plasmapheresis Refractory Antibody-Mediated Rejection
Acute antibody-mediated rejection (AMR) poses a significant risk to graft survival. Current or standard treatment (ST) of AMR currently consists of plasmapheresis (PP), intravenous immunoglobulin…2015 American Transplant Congress
Both Preformed and De Novo Cw Donor Specific Antibodies Are Clinically Significant in Renal Transplantation
Imperial College Kidney and Transplant Centre, Imperial College NHS, London, United Kingdom.
Preformed [PF] and de novo [DN] anti-HLA A, B, DR and DQ donor specific antibodies [DSAbs] are associated with poorer allograft outcomes secondary to antibody…2015 American Transplant Congress
DSA MFI Does Not Predict Late Antibody-Mediated Rejection Lesions Or Gene Expression Changes in Kidney Transplants
BACKGROUND: It is unclear whether donor-specific HLA antibody (DSA) levels at the time of a clinically-indicated biopsy can be predictive of the degree of antibody-mediated…2015 American Transplant Congress
Combination of Non-HLA and HLA-DSA Antibodies Identifies Liver Transplants Recipients With Highest Risk for Fibrosis Progression and Mortality
Recent data has shown an increased risk of fibrosis progression in HCV viremic liver transplant (LT) recipients with HLA DSA in serum. However, the role…2015 American Transplant Congress
DSA Detected by ELISA-PRA Is Associated With High Risk for Development of AMR in Stable Kidney Transplant Recipients
Background: Donor specific anti-HLA antibodies (DSA) are a major cause of antibody mediated rejection (AMR) and allograft loss, determining how to monitor patients for DSA…2015 American Transplant Congress
Desensitization Protocol Including Concomitant Bortezomib and Rituximab Did Not Reduce Calculated PRA Nor Mean MFI Values Among Waitlisted Patients for Deceased Donor Kidney Transplantation
Highly sensitized (HS) patients (pts) seldom have chance to receive deceased donor kidney transplant (DDKT). A desensitization (DES) program including bortezomib was employed to facilitate…
American Transplant Congress abstracts